Business Segments · Sales and marketing

Reportable Segment — Sales and marketing

Amgen Reportable Segment — Sales and marketing decreased by 3.5% to $1.10B in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 1.8%, from $1.12B to $1.10B.

Analysis

StatementSegment
First reportedQ1 2024
Last reportedQ3 2025
Rolls up toSales & Marketing
Metric ID: amgn_segment_reportable_segment_sales_and_marketing

Historical Data

6 periods
 Q1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25
Value$1.20B$1.21B$1.12B$1.07B$1.14B$1.10B
QoQ Change—+0.6%-7.8%-4.6%+6.7%-3.5%
YoY Change———-11.5%-6.1%-1.8%
Range$1.07B – $1.21B
CAGR-7.2%
Avg YoY Growth-6.5%
Median YoY Growth-6.1%

Frequently Asked Questions

What is Amgen's reportable segment — sales and marketing?
Amgen (AMGN) reported reportable segment — sales and marketing of $1.10B in Q3 2025.
How has Amgen's reportable segment — sales and marketing changed year-over-year?
Amgen's reportable segment — sales and marketing decreased by 1.8% year-over-year, from $1.12B to $1.10B.

Cookie Preferences

We use cookies for analytics. See our Privacy and Cookie Policy.